Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional pediatric cystic fibrosis center.
about
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosisAntibiotic adjuvant therapy for pulmonary infection in cystic fibrosisAntibiotic adjuvant therapy for pulmonary infection in cystic fibrosisAntibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosisOnset of persistent pseudomonas aeruginosa infection in children with cystic fibrosis with interval censored data.Uncovering symptom progression history from disease registry data with application to young cystic fibrosis patients.Neurotrophic and neuroimmune responses to early-life Pseudomonas aeruginosa infection in rat lungs.Transcriptional signatures as a disease-specific and predictive inflammatory biomarker for type 1 diabetesPseudomonas infection in antibody deficient patients.Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis.Change in Pseudomonas aeruginosa prevalence in cystic fibrosis adults over time.Impact of Sustained Eradication of New Pseudomonas aeruginosa Infection on Long-term Outcomes in Cystic Fibrosis.Nebulized antibiotic therapy: the evidence.Evolving epidemiology of Pseudomonas aeruginosa and the Burkholderia cepacia complex in cystic fibrosis lung infection.Recovery of birth weight z score within 2 years of diagnosis is positively associated with pulmonary status at 6 years of age in children with cystic fibrosis.Eradication of early Pseudomonas infection in cystic fibrosis.Optimizing treatment policies and improving care: impact on outcome in patients with cystic fibrosis.Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine.Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life.Current dilemmas in antimicrobial therapy in cystic fibrosis.Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.Fungal Pathogens in CF Airways: Leave or Treat?Virulence factor expression patterns in Pseudomonas aeruginosa strains from infants with cystic fibrosis.Halting the spread of epidemic pseudomonas aeruginosa in an adult cystic fibrosis centre: a prospective cohort study.Up-regulating pyocyanin production by amino acid addition for early electrochemical identification of Pseudomonas aeruginosa.Effects of segregation on an epidemic Pseudomonas aeruginosa strain in a cystic fibrosis clinic.Sputum issues as defined by patients with cystic fibrosis: a qualitative investigation.[Chronic Pseudomonas aeruginosa airway colonization in cystic fibrosis patients : Prevention concepts].Prevention of chronic Pseudomonas aeruginosa infection in people with cystic fibrosis.
P2860
Q24188054-9D4F7A66-E45C-445A-9D24-AFC147C6B1C6Q24202222-BBA5F490-613E-448E-B58E-BA269658A843Q24234613-16CFB98E-F1A2-49B1-9F48-EC6549C04D68Q24240388-62738140-2C03-4938-B78C-A9142A0BB5E0Q31131422-DFF1FC8B-F14B-47AA-876B-C40AFB397AB8Q33467002-6F8269F4-8F16-4E87-A533-42B724B64F94Q34180770-95E9A2D2-A3DC-44BF-BBE0-B5386CB47D14Q34693197-F825129C-07C5-4CF0-9882-B804D1AD2C11Q34743061-644C9585-0BC3-447E-A55B-60D0CA564840Q35127240-8E449E18-D64E-47E2-A79B-01480E282115Q36057093-DF2F5217-56DF-49AC-8966-656B18404F64Q36215326-4EE4A7B5-9A53-4EC9-BAC8-95A20A49884DQ36226940-8D0A4E96-1F1B-4315-8279-7A760A61DBC3Q36310044-16654728-5707-4A94-930C-D1C353E5AA49Q36895659-65D3DCE8-498B-4079-AEEE-8637CE4F4A8DQ37417046-A4436389-7C4E-4018-AD30-C34C206575E8Q37468065-A314A602-313B-4520-B48F-7B62DDEFD3D3Q37609433-C740C786-A5F6-4E3C-9CB4-73C7DDCA6DDBQ37738904-FE0431FA-5ED6-4FD2-A960-69BDF0A93892Q37844338-6AE0C138-F866-4C10-A446-014F0A578B86Q38042719-701C8ACD-D411-41AF-9BD5-FCD938BD8DE4Q38821019-2514986D-2043-4C6D-9C4F-5D396975F4B0Q40108783-27B77C87-A3AF-40DC-8C69-7D56B020533DQ42256090-E61D77B5-FA06-478B-A385-246E6ECBA254Q42274835-F7A0B000-F2EC-4322-A767-4BF42B8B41CFQ45300100-35A66A62-5D3F-4AF6-A4E5-60440059FFD9Q47849237-5C6B30D8-90E0-41BE-A7D6-5C24D9313B2FQ50679019-DD43FD3F-8B69-40F0-8E44-7021D17C82E1Q50865830-EF70DB5F-C643-4378-BE61-5CA8632C782BQ52847673-246933C0-7929-48E9-87D2-1283673E007A
P2860
Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional pediatric cystic fibrosis center.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Reduction in prevalence of chr ...... iatric cystic fibrosis center.
@en
Reduction in prevalence of chr ...... iatric cystic fibrosis center.
@nl
type
label
Reduction in prevalence of chr ...... iatric cystic fibrosis center.
@en
Reduction in prevalence of chr ...... iatric cystic fibrosis center.
@nl
prefLabel
Reduction in prevalence of chr ...... iatric cystic fibrosis center.
@en
Reduction in prevalence of chr ...... iatric cystic fibrosis center.
@nl
P2093
P356
P1476
Reduction in prevalence of chr ...... iatric cystic fibrosis center.
@en
P2093
James M Littlewood
Keith G Brownlee
Miles Denton
Steven P Conway
Tim W R Lee
P304
P356
10.1002/PPUL.10401
P577
2004-02-01T00:00:00Z